Enrique J. Carrazana, M.D.

Dr. Carrazana is currently Chief Medical Officer at San Diego–based specialty pharmaceutical company, Neurelis, Inc. which achieved Valtoco (intranasal diazepam spray) approval and orphan exclusivity for treatment acute repetitive seizures in Jan 2020. He has been a neuroscience drug development consultant since 2016. Dr. Carrazana is the former Chief Medical Officer of Acorda Therapeutics, Inc., where he was responsible for the management of drug development programs and regulatory filings, as well as the company’s medical affairs and drug safety departments. Previously, Dr. Carrazana held various medical leadership roles at Novartis, where his last role was Vice President, Global Head Development Established Medicines Franchise based in Basel, Switzerland.

Additionally, Dr. Carrazana was also Director of the Epilepsy Center of Excellence at the Miami Veterans’ Administration (VA) Hospital and Associate Professor of Neurology at the University of Miami Miller School of Medicine, and currently serves on the Board of Directors of Hawaii Biotech Inc. Dr. Carrazana is a board-certified neurologist with more than 20 years of experience in the pharmaceutical industry and clinical practice. He has presented and published a wide range of research on various neurology topics, with an emphasis on epilepsy. Dr. Carrazana received a MD from the Harvard Medical School and completed his residency in neurology and fellowship in neurophysiology at the Harvard Longwood Neurology Program.